Automated Determination of the H3 K27-Altered Status in Spinal Cord Diffuse Midline Glioma by Radiomics Based on T2-Weighted MR Images

References

1. 1.↵
   2. Fakhreddine MH,
   3. Mahajan A,
   4. Penas-Prado M, et al

   . Treatment, prognostic factors, and outcomes in spinal cord astrocytomas. Neuro Oncol 2013;15:406–12 doi:10.1093/neuonc/nos309 pmid:23322747

   CrossRefPubMed
2. 2.↵
   2. Abd-El-Barr MM,
   3. Huang KT,
   4. Moses ZB, et al

   . Recent advances in intradural spinal tumors. Neuro Oncol 2018;20:729–42 doi:10.1093/neuonc/nox230 pmid:29216380

   CrossRefPubMed
3. 3.↵
   2. Meyronet D,
   3. Esteban-Mader M,
   4. Bonnet C, et al

   . Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 2017;19:1127–34 doi:10.1093/neuonc/now274 pmid:28201752

   CrossRefPubMed
4. 4.↵
   2. Louis DN,
   3. Perry A,
   4. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
5. 5.↵
   2. Louis DN,
   3. Giannini C,
   4. Capper D, et al

   . cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639–42 doi:10.1007/s00401-018-1826-y pmid:29497819

   CrossRefPubMed
6. 6.↵
   2. Aquilanti E,
   3. Miller J,
   4. Santagata S, et al

   . Updates in prognostic markers for gliomas. Neuro Oncol 2018;20:vii17–26 doi:10.1093/neuonc/noy158 pmid:30412261

   CrossRefPubMed
7. 7.↵
   2. Yi S,
   3. Choi S,
   4. Shin DA, et al

   . Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord glioma on the basis of new 2016 World Health Organization Classification of the Central Nervous System. Neurosurgery 2019;84:1072–81 doi:10.1093/neuros/nyy150 pmid:29718432

   CrossRefPubMed
8. 8.↵
   2. Chai RC,
   3. Zhang YW,
   4. Liu YQ, et al

   . The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol Commun 2020;8:40 doi:10.1186/s40478-020-00913-w pmid:32228694

   CrossRefPubMed
9. 9.↵
   2. Akinduro OO,
   3. Garcia DP,
   4. Higgins DM, et al

   . A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma. J Neurosurg Spine 2021;35:834–43 doi:10.3171/2021.2.SPINE201675 pmid:34416733

   CrossRefPubMed
10. 10.↵
    2. Karremann M,
    3. Gielen GH,
    4. Hoffmann M, et al

    . Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol 2018;20:123–31 doi:10.1093/neuonc/nox149 pmid:29016894

    CrossRefPubMed
11. 11.↵
    2. Majzner RG,
    3. Ramakrishna S,
    4. Yeom KW, et al

    . GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022;603:934–41 doi:10.1038/s41586-022-04489-4 pmid:35130560

    CrossRefPubMed
12. 12.↵
    2. Gielen GH,
    3. Gessi M,
    4. Buttarelli FR, et al

    . Genetic analysis of diffuse high-grade astrocytomas in infancy defines a novel molecular entity. Brain Pathol 2015;25:409–17 doi:10.1111/bpa.12210 pmid:25231549

    CrossRefPubMed
13. 13.↵
    2. Thust SC,
    3. Heiland S,
    4. Falini A, et al

    . Glioma imaging in Europe: a survey of 220 centres and recommendations for best clinical practice. Eur Radiol 2018;28:3306–17 doi:10.1007/s00330-018-5314-5 pmid:29536240

    CrossRefPubMed
14. 14.↵
    2. Rudie JD,
    3. Rauschecker AM,
    4. Bryan RN, et al

    . Emerging applications of artificial intelligence in neuro-oncology. Radiology 2019;290:607–18 doi:10.1148/radiol.2018181928 pmid:30667332

    CrossRefPubMed
15. 15.↵
    2. Bhandari AP,
    3. Liong R,
    4. Koppen J, et al

    . Noninvasive determination of IDH and 1p19q status of lower-grade gliomas using MRI radiomics: a systematic review. AJNR Am J Neuroradiol 2021;42:94–101 doi:10.3174/ajnr.A6875 pmid:33243896

    Abstract/FREE Full Text
16. 16.↵
    2. Su X,
    3. Chen N,
    4. Sun H, et al

    . Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain. Neuro Oncol 2020;22:393–401 doi:10.1093/neuonc/noz184 pmid:31563963

    CrossRefPubMed
17. 17.↵
    2. Zhuo Z,
    3. Qu L,
    4. Zhang P, et al

    . Prediction of H3K27M-mutant brainstem glioma by amide proton transfer-weighted imaging and its derived radiomics. Eur J Nucl Med Mol Imaging 2021;48:4426–36 doi:10.1007/s00259-021-05455-4 pmid:34131804

    CrossRefPubMed
18. 18.↵
    2. Jung JS,
    3. Choi YS,
    4. Ahn SS, et al

    . Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging. Neuroradiology 2019;61:313–22 doi:10.1007/s00234-019-02154-8 pmid:30662997

    CrossRefPubMed
19. 19.↵
    2. Cheng L,
    3. Wang L,
    4. Yao Q, et al

    . Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma. J Neurosurg Spine 2021;36:1–12 doi:10.3171/2021.4.SPINE2140 pmid:34560639

    CrossRefPubMed
20. 20.↵
    2. Kim DH,
    3. Kim JH,
    4. Choi SH, et al

    . Differentiation between intramedullary spinal ependymoma and astrocytoma: comparative MRI analysis. Clin Radiol 2014;69:29–35 doi:10.1016/j.crad.2013.07.017 pmid:24034546

    CrossRefPubMed
21. 21.↵
    2. Timpone VM,
    3. Patel SH

    . MRI of a syrinx: is contrast material always necessary? AJR Am J Roentgenol 2015;204:1082–85 doi:10.2214/AJR.14.13310 pmid:25905945

    CrossRefPubMed
22. 22.↵
    2. Lemay A,
    3. Gros C,
    4. Zhuo Z, et al

    . Automatic multiclass intramedullary spinal cord tumor segmentation on MRI with deep learning. Neuroimage Clin 2021;31:102766 doi:10.1016/j.nicl.2021.102766 pmid:34352654

    CrossRefPubMed
23. 23.↵
    2. Sun T,
    3. Wang Y,
    4. Liu X, et al

    . Deep learning based on preoperative magnetic resonance (MR) images improves the predictive power of survival models in primary spinal cord astrocytomas. Neuro Oncol 2023;25:1157–65 doi:10.1093/neuonc/noac280 pmid:36562243

    CrossRefPubMed
24. 24.↵
    2. Wang L,
    3. Li Z,
    4. Zhang M, et al

    . H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol 2018;78:89–96 doi:10.1016/j.humpath.2018.04.015 pmid:29727696

    CrossRefPubMed
25. 25.↵
    2. Piccardo A,
    3. Tortora D,
    4. Mascelli S, et al

    . Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas. Eur J Nucl Med Mol Imaging 2019;46:1685–94 doi:10.1007/s00259-019-04333-4 pmid:31030232

    CrossRefPubMed
26. 26.↵
    2. Qiu T,
    3. Chanchotisatien A,
    4. Qin Z, et al

    . Imaging characteristics of adult H3 K27M-mutant gliomas. J Neurosurg 2019;133:1662–70 doi:10.3171/2019.9.JNS191920 pmid:31731269

    CrossRefPubMed
27. 27.↵
    2. Schulte JD,
    3. Buerki RA,
    4. Lapointe S, et al

    . Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv 2020;2:vdaa142 doi:10.1093/noajnl/vdaa142 pmid:33354667

    CrossRefPubMed
28. 28.↵
    2. Schreck KC,
    3. Ranjan S,
    4. Skorupan N, et al

    . Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 2019;143:87–93 doi:10.1007/s11060-019-03134-x pmid:30864101

    CrossRefPubMed
29. 29.↵
    2. Wang YZ,
    3. Zhang YW,
    4. Liu WH, et al

    . Spinal cord diffuse midline gliomas with H3 K27m-mutant: clinicopathological features and prognosis. Neurosurgery 2021;89:300–07 doi:10.1093/neuros/nyab174 pmid:34015818

    CrossRefPubMed
30. 30.↵
    2. Kandemirli SG,
    3. Kocak B,
    4. Naganawa S, et al

    . Machine learning-based multiparametric magnetic resonance imaging radiomics for prediction of H3K27M mutation in midline gliomas. World Neurosurg 2021;151:e78–85 doi:10.1016/j.wneu.2021.03.135 pmid:33819703

    CrossRefPubMed
31. 31.↵
    2. Pan CC,
    3. Liu J,
    4. Tang J, et al

    . A machine learning-based prediction model of H3K27M mutations in brainstem gliomas using conventional MRI and clinical features. Radiother Oncol 2019;130:172–79 doi:10.1016/j.radonc.2018.07.011 pmid:30097251

    CrossRefPubMed
32. 32.↵
    2. Nagaraja S,
    3. Quezada MA,
    4. Gillespie SM, et al

    . Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state. Mol Cell 2019;76:965–80.e12 doi:10.1016/j.molcel.2019.08.030 pmid:31588023

    CrossRefPubMed
33. 33.↵
    2. Castel D,
    3. Philippe C,
    4. Calmon R, et al

    . Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015;130:815–27 doi:10.1007/s00401-015-1478-0 pmid:26399631

    CrossRefPubMed